Background. The synthetic DNA-based immunomodulator MGN1703 acts as an agonist of toll-like receptor 9. Based on promising data from a phase 1 study in patients with metastatic solid tumors including those with CRC, a phase 2-3 study was initiated in patients with advanced CRC having disease control after first-line therapy. The objective of the study is to assess efficacy and safety of the MGN1703 treatment in comparison to placebo. Methods. The IMPACT study is designed as a randomized double-blind placebo-controlled phase 2-3 study, in which patients with advanced CRC showing disease control after first-line therapy with standard chemotherapy regimen are included. The treatment (60 mg MGN1703 or placebo) is administered subcutaneously twice weekly in a ratio 2:1. The study is conducted in Germany, Austria, France, UK, Czech Republic and Russia, and 129 patients will be recruited into the study. The efficacy and safety of the study treatment will be evaluated based on extensive immunological tests, radiological assessment, safety laboratory results and assessments of the quality of life. The study treatment will be continued until tumor progression, intolerable toxicity, exclusion criteria or withdrawal of consent.
R e s u l t s R e s u l t s C o n c l u s i o n s C o n c l u s i o n s
• The preliminary results show clearly that treatment with a dosage of 60 mg MGN1703 is well tolerated and safe in patients with advanced CRC after "first-line" therapy.
• The reactions such as mild fever and injection site reactions in single patients are expected due to the mode of action of the study drug MGN1703.
C C o n t a c t o n t a c t
Study medication. MGN1703 is a synthetic DNA-based immunomodulator with a dumbbell-like structure, exhibiting no chemical modification (Figure 1 ). MGN1703 acts as an agonist of toll-like receptor 9, activates both innate and adaptive immune response and has shown a very good safety profile and promising signs of efficacy in a previous phase 1 study in patients with advanced solid tumors (MGN1703-C01).
Patient disposition.
One hundred and twenty nine patients with advanced CRC with disease control after "first-line" induction therapy have to be recruited to the study and randomized to be treated either with MGN1703 or with placebo (with a ratio of 2:1), respectively. The mean age of the included CRC patients is 63.5 years. Currently, the mean treatment duration is 16.5 weeks with the longest ongoing treatment of 66 weeks. The mean number of application is 32.1 with the highest number of applications is 132 so far.
Study details.
The study is an international multicentric randomized placebo-controlled phase 2/3 clinical study for the maintenance treatment of patients with advanced CRC with disease control after "first-line" induction therapy with standard chemotherapy regimen with or without bevacizumab (Figure 2 ).
Design. This is a double-blind randomized placebo-controlled study with two arms in which 129 patients will be included with a ratio of 2 to 1:
• 86 patients into the verum arm (MGN1703)
• 43 patients into the placebo arm. Inclusion. The standard "first-line" therapy needed for patient inclusion must consist of:
• a therapy with FOLFOX / FOLFIRI / XELOX with or without bevacizumab for 4.5 to 6.0 months
• including at least 3 months with Irinotecan / Oxaliplatin • and show at least disease stabilization after "first-line" therapy.
Treatment. The recruited patients are treated twice a week with subcutaneous administration of 60 mg MGN1703 as maintenance therapy. This dose has been proven to be safe in the previous phase 1 clinical study.
Evaluation. The efficacy and safety of the study treatment will be evaluated based on extensive immunological tests (flow cytometry, cytokines, functional tests), radiological assessment (RECIST), evaluation of safety parameters and assessments of the quality of life.
Treatment duration. The treatment will be continued up to occurrence of tumor progression, intolerable toxicity, exclusion criteria, withdrawal of consent or death.
Study centers. The study sites are located in Germany, Austria, France, United Kingdom, Russia and Czech Republic.
Safety profile.
As the previous phase 1 study in patients with advance solid tumors already showed, treatment with MGN1703 is well tolerated in patients with advanced CRC as well.
Adverse events. Out of all observed adverse events (AE) the majority (over 84%) were judged as not drug-related by the investigators. The remaining AE were shown in Table 1 .
Serious adverse events. Nine serious adverse events (SAE) have been reported so far of which only one was assessed as probably drug-related by the investigator: atypical pneumonia. This event occurred in patient 097 (see Table 1 ).
Local reactions. Local reactions in terms of mild redness, swelling at injection site, itching at injection area were reported in single patients. No signs of local intolerability after multiple dose application was observed. 
